Skip to main content
. 2016 Feb 8;263(3):465–476. doi: 10.1097/SLA.0000000000001366

TABLE 2.

Intraoperative Fluid Infused in the Goal-directed and Control Groups

Reference Average Total Fluid Infused (mL) Average Crystalloid (mL) Average Colloid Bolus (mL) Average Blood Loss (mL) Requirement for Perioperative Inotropes
GDFT Control GDFT Control GDFT Control GDFT Control GDFT Control
Pestana 201428 2500 (1625–3000) 2325 (1600–3000) Not stated Not stated 2.4 boluses ± 1.8* 1.3 boluses ± 1.4* 300 (200–500) 250 (200–400) 18 dobutamine, 5 noradrenaline, 25 ephedrine 1 dobutamine, 4 noradrenaline, 22 ephedrine
Phan 201421 2190 (1350–2560)* 1500 (1200–2000)* 1500 (1000–2000) 1400 (1000–1900) 500 (250–750)* 0 (0–300)* Not stated Not stated Not stated Not stated
Zeng 201429 2732 ± 488* 3135 ± 346* Not stated Not stated 1225 ± 360* 760 ± 280* 482 ± 168 473 ± 156 Not stated Not stated
Zheng 201330 2650 (2400–3200)* 3950 (2875–4200)* 1550 (1400–1925)* 2350 (2000–2925)* 1000 (900–1100)* 800 (600–1000)* 200 (100–362.5) 200 (100–800) 4 (13.3) 6 (20)
Salzwedel 201331 3854.2 ± 1954.2 3770.8 ± 2827.5 2862 ± 1216 2680.2 ± 1153.8 773.7 ± 664.6 724.7 ± 720.2 668.2 ± 676.6 704.4 ± 889.6 33 dobutamine*, 26 norepinephrine, 0 phenylephrine, 11 ephedrine 0 dobutamine*, 32 norepinephrine, 4 phenylephrine, 8 ephedrine
Scheeren 201332 4477 (2107) 4528 (2387) Not stated Not stated 1589 (1283)* 927 (845)* 984 (647) 1118 (1057) Norepinephrine dosage 0.04 μg/kg/min (0.06) 0.05 μg/kg/min (0.05)
Ramsingh 201333 4082.2 ± 2044* 6845.6 ± 3893.4* 3343.3 ± 1563.7* 5851.5 ± 3197.9* 544.4 ± 493.5 422.5 ± 590.8 Not stated Not stated Not stated Not stated
Bundgaard-Nielsen 201334 Not stated Not stated 1879 (1205–2052) 1636 (1428–1843) 1758 (1441–2076)* 1057 (778–1336)* 1285 (875–1696) 1152 (774–1530) Average 9 mg ephedrine (4–13) Average 15 mg ephedrine (8–22)
McKenny 201335 2620 2881 1000 (787–1750)* 2000 (1725–2500)* 1000 (1000–1500)* 500 (0–1000)* 500 (311–745) 600 (326–1000) Not stated Not stated
Srinivasa 201336 1994 (590)* 1614 (420)* Not stated Not stated 591 (471)* 297 (275)* Not stated Not stated 31 (83.7) 34 (91.9)
Zakhaleva 201338 3100 (700–77000) 4000 (900–6200) 2700 (500–6500) 3200 (500–5600) 500 (0–2800)* 300 (0–4500)* 100 (10–650) 100 (10–500) Not stated Not stated
Brandstrup 201237 1876* 1491* Saline and LR: 483 (419) 443 (480) 810 (543)* 475 (598)* Not stated Not stated Not stated Not stated
Challand 201239 Not stated Not stated 3479 (1181) 3593 (1398) 1718 (446)* 336 (623)* 500 (200–1000)* 250 (100–500)* Not stated Not stated
Pillai 201140 0.23 mL/kg/min (0.21–0.25)* 0.19 mL/kg/min (0.15–0.2)* Not stated Not stated Not stated Not stated 9.82 mL/kg (95% CI 7.53–12.12) 10.7 mL/kg (8.42–12.9) Not stated Not stated
Forget 201041 2394 (2097–2692)* 2918 (2478–3358)* 1363 (1185–1540)* 1815 (1568–2064)* 890 (709–1072) 1003 (779–1227) 349 (230–468) 440 (242–637) 9 continuous norepinephrine infusion 9 continuous norepinephrine infusion
Benes 201042 Not stated Not stated 2321 ± 681 2459 ± 930 1425 (1000–1500)* 1000 (540–1250)* 700 (500–1200) 800 (400–1325) 3 (5.88%) norepinephrine, 2 (3.92%) dobutamine 11 (20.37%) norepinephrine, 0 dobutamine
Buettner 200843 6000 5250 Not stated Not stated Not stated Not stated Not stated Not stated 30 29
Lopes 200744 4618 ± 1557* 1694 ± 705* 2176 ± 1060 1563 ± 02 2247 ± 697* 0* Not stated Not stated Not stated Not stated
Noblett 20066 Not stated Not stated 2298 (863) 2625 (1004) 1340 (838) 1209 (824) 250 (40–2455) 475 (100–2900) 16 (31)* 26 (50) *
Wakeling 200545 Not stated Not stated 3000 3000 2000* 1500* 500 (700) 500 (975) Not stated Not stated
Conway 200246 64.6 mL/kg (36.4) 55.2 mL/kg (24) Not stated Not stated 28 mL/kg (16) 19.4 mL/kg (14.7) Not stated Not stated Not stated Not stated
Gan 20027 Not stated Not stated 4405 ± 2650 4375 ± 2452 847 ± 373* 282 ± 470* 703 ± 649 624 ± 632 8 (16) 13 (26)
Bonazzi 200247 4500 (3250–6500)* 3250 (2500–4750)* Not stated Not stated Not stated Not stated 1000 (450–2750) 1100 (500–2500) Not stated Not stated

*Indicates statistically significant difference between GDFT and control groups.